CL2020001132A1 - Composiciones farmacéuticas orales de lorazepam resistentes al alcohol. - Google Patents

Composiciones farmacéuticas orales de lorazepam resistentes al alcohol.

Info

Publication number
CL2020001132A1
CL2020001132A1 CL2020001132A CL2020001132A CL2020001132A1 CL 2020001132 A1 CL2020001132 A1 CL 2020001132A1 CL 2020001132 A CL2020001132 A CL 2020001132A CL 2020001132 A CL2020001132 A CL 2020001132A CL 2020001132 A1 CL2020001132 A1 CL 2020001132A1
Authority
CL
Chile
Prior art keywords
alcohol
lorazepam
resistant
pharmaceutical compositions
oral pharmaceutical
Prior art date
Application number
CL2020001132A
Other languages
English (en)
Inventor
Douglas Saltel
Michael Vachon
Original Assignee
Edgemont Pharmaceuticals Llc Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edgemont Pharmaceuticals Llc Trust filed Critical Edgemont Pharmaceuticals Llc Trust
Publication of CL2020001132A1 publication Critical patent/CL2020001132A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen composiciones farmacéuticas orales resistentes al alcohol y formas de dosificación que presentan una liberación del fármaco reducida en la presencia del alcohol. Las composiciones comprenden un sustrato que comprende una formulación de liberación controlada de lorazepam y un recubrimiento resistente al alcohol que rodea el sustrato.
CL2020001132A 2017-11-01 2020-04-29 Composiciones farmacéuticas orales de lorazepam resistentes al alcohol. CL2020001132A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762580321P 2017-11-01 2017-11-01

Publications (1)

Publication Number Publication Date
CL2020001132A1 true CL2020001132A1 (es) 2020-08-21

Family

ID=64184278

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001132A CL2020001132A1 (es) 2017-11-01 2020-04-29 Composiciones farmacéuticas orales de lorazepam resistentes al alcohol.

Country Status (18)

Country Link
US (1) US11806433B2 (es)
EP (1) EP3703664A1 (es)
JP (1) JP7110366B2 (es)
KR (1) KR20200078601A (es)
CN (1) CN111278434A (es)
AU (1) AU2018362263B2 (es)
BR (1) BR112020008756A2 (es)
CA (1) CA3080702C (es)
CL (1) CL2020001132A1 (es)
CO (1) CO2020006701A2 (es)
IL (1) IL274187A (es)
MX (1) MX2020004546A (es)
PE (1) PE20211271A1 (es)
PH (1) PH12020550456A1 (es)
RU (1) RU2020117757A (es)
SG (1) SG11202003439WA (es)
WO (1) WO2019089330A1 (es)
ZA (1) ZA202002086B (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW330907B (en) * 1996-09-09 1998-05-01 Riso Kagaku Corp The ink container and ink supplied device for packing ink container
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
JP5704789B2 (ja) 2005-01-28 2015-04-22 ユーロ−セルティーク エス．エイ． 耐アルコール性剤形
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
JP5651818B2 (ja) * 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド 誤用を防止するための放出制御製剤
SG10201504529WA (en) 2010-03-09 2015-07-30 Alkermes Pharma Ireland Ltd Alcohol Resistant Enteric Pharmaceutical Compositions
MY166034A (en) 2010-12-22 2018-05-21 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
SG11201505352RA (en) 2013-01-09 2015-08-28 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US10751287B2 (en) * 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ES2838816T3 (es) * 2015-06-05 2021-07-02 Evonik Operations Gmbh Composición farmacéutica o nutracéutica con resistencia contra la influencia de etanol

Also Published As

Publication number Publication date
RU2020117757A (ru) 2021-11-29
ZA202002086B (en) 2022-12-21
RU2020117757A3 (es) 2021-11-29
JP2021501197A (ja) 2021-01-14
EP3703664A1 (en) 2020-09-09
CA3080702C (en) 2022-10-18
PE20211271A1 (es) 2021-07-19
AU2018362263A1 (en) 2020-05-14
WO2019089330A1 (en) 2019-05-09
MX2020004546A (es) 2020-10-05
US11806433B2 (en) 2023-11-07
AU2018362263B2 (en) 2021-08-12
BR112020008756A2 (pt) 2020-10-13
SG11202003439WA (en) 2020-05-28
KR20200078601A (ko) 2020-07-01
IL274187A (en) 2020-06-30
US20200375906A1 (en) 2020-12-03
PH12020550456A1 (en) 2021-03-15
CN111278434A (zh) 2020-06-12
CO2020006701A2 (es) 2020-06-09
CA3080702A1 (en) 2019-05-09
JP7110366B2 (ja) 2022-08-01

Similar Documents

Publication Publication Date Title
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
NI201900004A (es) Composición vaginal comprendiendo una combinación de estrógeno y vitamina d.
CL2018002368A1 (es) Formulaciones de oritavancina
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CL2017002229A1 (es) Inhibidores de bace1.
CL2016000543A1 (es) Uso de pidotimod o sus estereoisómeros y/o sales fisiológicamente aceptables para preparar un medicamento útil en el tratamiento de enfermedades asociadas con la inflamación, donde hay una hiperactivación aberrante de la vía no canónica de nfkb.
CO2020006701A2 (es) Composiciones farmacéuticas orales de lorazepam resistentes al alcohol
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
UY37518A (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
UY37413A (es) Formulaciones de liberación inmediata de oprozomib